| Product Code: ETC7657109 | Publication Date: Sep 2024 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Israel Nivolumab Market Overview |
3.1 Israel Country Macro Economic Indicators |
3.2 Israel Nivolumab Market Revenues & Volume, 2021 & 2031F |
3.3 Israel Nivolumab Market - Industry Life Cycle |
3.4 Israel Nivolumab Market - Porter's Five Forces |
3.5 Israel Nivolumab Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Israel Nivolumab Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.7 Israel Nivolumab Market Revenues & Volume Share, By Demographic, 2021 & 2031F |
3.8 Israel Nivolumab Market Revenues & Volume Share, By Dosage, 2021 & 2031F |
3.9 Israel Nivolumab Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.10 Israel Nivolumab Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.11 Israel Nivolumab Market Revenues & Volume Share, By Dosage, 2021 & 2031F |
4 Israel Nivolumab Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing incidences of cancer in Israel |
4.2.2 Growing adoption of immunotherapy treatments |
4.2.3 Rising investments in healthcare infrastructure |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approvals |
4.3.2 High costs associated with nivolumab treatment |
4.3.3 Limited awareness and access to advanced cancer treatments |
5 Israel Nivolumab Market Trends |
6 Israel Nivolumab Market, By Types |
6.1 Israel Nivolumab Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Israel Nivolumab Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 Israel Nivolumab Market Revenues & Volume, By 40 mg/4 mL, 2021- 2031F |
6.1.4 Israel Nivolumab Market Revenues & Volume, By 100 mg/10 mL, 2021- 2031F |
6.1.5 Israel Nivolumab Market Revenues & Volume, By 240 mg/24 mL, 2021- 2031F |
6.2 Israel Nivolumab Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 Israel Nivolumab Market Revenues & Volume, By Melanoma, 2021- 2031F |
6.2.3 Israel Nivolumab Market Revenues & Volume, By Non-small Cell Lung Cancer (NSCLC), 2021- 2031F |
6.2.4 Israel Nivolumab Market Revenues & Volume, By Malignant Pleural Mesothelioma, 2021- 2031F |
6.2.5 Israel Nivolumab Market Revenues & Volume, By Classical Hodgkin Lymphoma (CHL), 2021- 2031F |
6.2.6 Israel Nivolumab Market Revenues & Volume, By Squamous Cell Carcinoma of the Head and Neck (SCCHN), 2021- 2031F |
6.2.7 Israel Nivolumab Market Revenues & Volume, By Renal Cell Carcinoma (RCC), 2021- 2031F |
6.3 Israel Nivolumab Market, By Demographic |
6.3.1 Overview and Analysis |
6.3.2 Israel Nivolumab Market Revenues & Volume, By Adult, 2021- 2031F |
6.3.3 Israel Nivolumab Market Revenues & Volume, By Pediatric, 2021- 2031F |
6.4 Israel Nivolumab Market, By Dosage |
6.4.1 Overview and Analysis |
6.4.2 Israel Nivolumab Market Revenues & Volume, By Injection, 2021- 2031F |
6.4.3 Israel Nivolumab Market Revenues & Volume, By Solution, 2021- 2031F |
6.4.4 Israel Nivolumab Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Israel Nivolumab Market, By Route of Administration |
6.5.1 Overview and Analysis |
6.5.2 Israel Nivolumab Market Revenues & Volume, By Intravenous, 2021- 2031F |
6.5.3 Israel Nivolumab Market Revenues & Volume, By Others, 2021- 2031F |
6.6 Israel Nivolumab Market, By End-Users |
6.6.1 Overview and Analysis |
6.6.2 Israel Nivolumab Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.6.3 Israel Nivolumab Market Revenues & Volume, By Clinics, 2021- 2031F |
6.6.4 Israel Nivolumab Market Revenues & Volume, By Others, 2021- 2031F |
6.7 Israel Nivolumab Market, By Dosage |
6.7.1 Overview and Analysis |
6.7.2 Israel Nivolumab Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.7.3 Israel Nivolumab Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.7.4 Israel Nivolumab Market Revenues & Volume, By , 2021- 2031F |
6.8 Israel Nivolumab Market, By Distribution Channel |
6.8.1 Overview and Analysis |
6.8.2 Israel Nivolumab Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.8.3 Israel Nivolumab Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.8.4 Israel Nivolumab Market Revenues & Volume, By , 2021- 2031F |
7 Israel Nivolumab Market Import-Export Trade Statistics |
7.1 Israel Nivolumab Market Export to Major Countries |
7.2 Israel Nivolumab Market Imports from Major Countries |
8 Israel Nivolumab Market Key Performance Indicators |
8.1 Patient survival rates post-nivolumab treatment |
8.2 Number of clinical trials and research studies conducted on nivolumab in Israel |
8.3 Percentage of oncologists recommending nivolumab as a treatment option |
8.4 Rate of adverse reactions reported for nivolumab treatment |
8.5 Number of partnerships and collaborations for nivolumab development in Israel |
9 Israel Nivolumab Market - Opportunity Assessment |
9.1 Israel Nivolumab Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Israel Nivolumab Market Opportunity Assessment, By Application, 2021 & 2031F |
9.3 Israel Nivolumab Market Opportunity Assessment, By Demographic, 2021 & 2031F |
9.4 Israel Nivolumab Market Opportunity Assessment, By Dosage, 2021 & 2031F |
9.5 Israel Nivolumab Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.6 Israel Nivolumab Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.7 Israel Nivolumab Market Opportunity Assessment, By Dosage, 2021 & 2031F |
9.7 Israel Nivolumab Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Israel Nivolumab Market - Competitive Landscape |
10.1 Israel Nivolumab Market Revenue Share, By Companies, 2024 |
10.2 Israel Nivolumab Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here